AusperBio
Develops oligonucleotide therapeutics targeting chronic hepatitis B
$120MSeries C
Role not disclosedQV
Qiming Venture Partners
Activity from announced rounds
Activity in this selectionSeries C+
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $190M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionOricell Therapeutics
Develops next-generation cell therapies for oncology and immunology
$70MSeries C1
Role not disclosed